Pharma BD Deal Intelligence
An all-stock, high-conviction swing still pending: Liminatus is paying $320M in shares (1.6 billion at $0.20) plus a 20% contingent value right for InnocsAI's CD19xCD22 CAR-T in DLBCL, but the deal still needs a stockholder vote before the December 31, 2026 outside date.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →This proposed transaction represents a transformational opportunity for Liminatus to expand into next-generation oncology cell therapies, said Chris Kim, Chief…
InnocsAI holders receive 1.6 billion shares of Liminatus common stock at an issue price of $0.20 per share plus contingent value rights for 20% of future net…
Liminatus Pharma has agreed to acquire CAR-T biotechnology firm InnocsAI in a share-based transaction valued at US$320 million. The acquisition involves…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Liminatus Pharma (Nasdaq: LIMN) entered a definitive merger agreement dated May 17, 2026 (announced May 21, 2026) to combine with private oncology cell-therapy company InnocsAI. Existing InnocsAI members would receive aggregate consideration of 1,600,000,000 Liminatus common shares at a $0.20 issue price (~$320 million), plus contingent value rights to 20% of net proceeds from any future strategic sale, out-license, transfer or exit of the acquired InnocsAI assets. The deal adds CAR-T and antibody-based oncology programs, including a CD19xCD22 bispecific CAR-T candidate in Phase 1/2a in South Korea for relapsed/refractory diffuse large B-cell lymphoma. Closing is conditioned on a Liminatus stockholder vote at a special meeting and customary conditions; either party may terminate if the merger has not closed by the December 31, 2026 outside date. The all-stock consideration carries elevated risk: on May 20, 2026 Liminatus received a Nasdaq delisting determination for failing to regain compliance with the $50M Market Value of Listed Securities rule and the $15M Market Value of Publicly Held Shares rule. Liminatus appealed to the Nasdaq Hearings Panel on May 26, 2026, which stays any suspension or delisting pending the hearing. As of this review (June 7, 2026) the merger remains pending — neither closed nor terminated.
28K US cases/yr · $3.1B 2024 US CAR-T market for B-cell malignancies
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, accounting for approximately 30% of NHL cases. The US sees roughly 28,000-31,000 new DLBCL cases annually per SEER and ASH analyses. First-line R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone) cures approximately 60% of patients; the remaining 40% relapse or are refractory and require salvage therapy. Autologous CD19-directed CAR-T therapies (Gilead/Kite's Yescarta, BMS's Breyanzi, Novartis's Kymriah) have reshaped the second- and third-line setting with durable complete response rates of 40-60% in registrational trials, but resistance via CD19 antigen loss/downregulation is a recognized failure mode affecting roughly one-third of relapsed patients. Dual-antigen CAR-T candidates targeting both CD19 and CD22 aim to mitigate CD19 escape and broaden the responder population. The US CAR-T market for B-cell malignancies was approximately $3.1 billion in 2024 and the global DLBCL market is projected to exceed $16.5 billion by 2034. CD19xCD22 bivalent CAR-T candidates including Caribou's CB-010 (allogeneic), Autolus' obe-cel (CD19 only, approved as Aucatzyl), and academic dual-target constructs are in mid-stage development globally; IBC101 advances dual-targeting in a South Korean clinical setting.
DLBCL CAR-T is dominated commercially by Gilead/Kite's Yescarta (axi-cel) and BMS's Breyanzi (liso-cel), with Novartis's Kymriah (tisa-cel) trailing. Both Yescarta and Breyanzi have moved into second-line treatment for patients refractory to or relapsing within 12 months of frontline therapy. Antigen escape via CD19 loss remains the principal resistance mechanism for single-target CAR-T, motivating development of CD19xCD22 bivalent constructs including academic candidates (UPenn AUTO3, NCI) and Caribou's CB-010 allogeneic dual-target program. IBC101 enters as an autologous bivalent CD19xCD22 CAR-T with Phase 1/2a clearance from Korea's MFDS and Seoul St. Mary's Hospital as lead site, plus solid-tumor preclinical assets (INC101/INC102 MSLNxCD276) and a CS1 antibody platform supporting future trivalent CD19xCD22xCS1 constructs. The strategic logic is contested: Liminatus is a financially distressed CD47-platform SPAC trading at ~$0.25, facing potential Nasdaq delisting with negative free cash flow of -$9.98M, paying entirely in deeply discounted stock plus a 20% CVR on future asset proceeds.
On May 20, 2026 — one day before announcing the InnocsAI merger — Liminatus received a Nasdaq delisting determination for failing to regain compliance with the $50M Market Value of Listed Securities rule (5450(b)(2)(A)) and the $15M Market Value of Publicly Held Shares rule (5450(b)(2)(C)). Liminatus appealed to the Nasdaq Hearings Panel on May 26, 2026, staying any suspension/delisting pending the hearing. The merger consideration is all Liminatus stock, so the listing risk bears directly on deal value.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Liminatus Pharma, Inc. / InnocsAI, Inc. (this deal) | 2026 | $320M | — |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Otsuka Pharmaceutical Co. Ltd. / Astex Pharmaceuticals | 2013 | $886M | 79 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
← Browse all deals · How we score deals
More: 2026 deals · Hematology deals